PROF Archives - BioTuesdays

Developments

Profound Medical’s Autonomous Robotics and Incisionless Surgery to Have Strong Presence at SRS2026

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) announced that its MRI-guided, AI-powered, Robotically-Driven and Incisionless TULSA Procedure will be highlighted in several presentations by leading physicians at the...

July 15, 2026

Markets

Paradigm Capital names Perimeter and maintains Profound as healthcare Top Picks

Paradigm Capital has named Perimeter Medical Imaging AI (TSXV:PINK; OTCQX:PYNKF) as a new Top Pick with a “speculative buy” rating and C$0.95 price target. The stock closed at C$0.275 on July 3. Commenting on the FDA’s...

July 6, 2026

Developments

The iMRI revolution gets another boost from AiM’s collaboration with Siemens to advance robotic neurosurgery

Closely held AiM Medical Robotics has announced a collaboration agreement with Siemens Healthineers (FSE: SHL) for the implementation of an interface enabling AiM’s robotic platform to operate with MRI systems...

May 27, 2026

Developments

Telix in PSMA collaboration with Profound Medical and other prostate cancer therapy players

Telix Pharmaceuticals (ASX:TLX, NASDAQ:TLX) announced that it has entered into letters of intent to pursue collaborations to explore the investigational use of its PSMA-PET imaging agents Gozellix (kit for the...

May 15, 2026

Developments

SIR highlights Profound’s CAPTAIN study results showing faster recovery with TULSA v robotic prostate surgery

The Society of Interventional Radiology (SIR) has highlighted the results of Profound Medical’s (NASDAQ: PROF; TSX: PRN) randomized post-market CAPTAIN trial demonstrating that men with localized, intermediate-risk...

April 14, 2026

Developments

Profound congratulates Texas Prostate’s 100th TULSA Procedure milestone

Profound Medical (NASDAQ:PROF; TSX:PRN) has announced that Texas Prostate, led by Dr. James Cochran, has achieved its 100th TULSA Procedure performed in Dallas Medical Center’s state-of-the-art MRI suite. “Having...

March 27, 2026

Developments

Trial finds Profound’s TULSA Procedure significantly improves erectile function and continence vs. robotic radical prostatectomy

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced superiority on the prespecified, primary safety endpoint in the Level 1 post-market CAPTAIN randomized controlled trial comparing the TULSA Procedure with robotic...

March 16, 2026

Developments

INOVAIT honors Profound with 2025/26 Mount Logan Award recognizing Tulsa Procedure for prostate disease

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced that it has received the 2025/2026 Mount Logan Award from INOVAIT, the Canadian national network for commercializing breakthroughs in image-guided therapy and AI...

February 12, 2026

Developments

PRO FAMILIA and Profound mark 500 Sonalleve Procedures; expand access to incision-free women’s healthcare

Profound Medical (NASDAQ:PROF; TSX:PRN) announced today that PRO FAMILIA Specialist Hospital in Rzeszów, Poland has completed its 500th Sonalleve Procedure. The MRI-guided therapy provides women with a non-surgical...

February 5, 2026

Developments

Mount Sinai becomes first in NYC to deliver incision-free, MRI-guided prostate treatment with Profound’s TULSA-PRO

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced that the world-renowned Mount Sinai Hospital, Metro New York (NYC), has successfully treated its first prostate cancer patient with the TULSA-PRO system. The TULSA...

January 15, 2026

Tag - PROF

Profound Medical’s Autonomous Robotics and Incisionless Surgery to Have Strong Presence at SRS2026

Paradigm Capital names Perimeter and maintains Profound as healthcare Top Picks

The iMRI revolution gets another boost from AiM’s collaboration with Siemens to advance robotic neurosurgery

Telix in PSMA collaboration with Profound Medical and other prostate cancer therapy players

SIR highlights Profound’s CAPTAIN study results showing faster recovery with TULSA v robotic prostate surgery

Profound congratulates Texas Prostate’s 100th TULSA Procedure milestone

Trial finds Profound’s TULSA Procedure significantly improves erectile function and continence vs. robotic radical prostatectomy

INOVAIT honors Profound with 2025/26 Mount Logan Award recognizing Tulsa Procedure for prostate disease

PRO FAMILIA and Profound mark 500 Sonalleve Procedures; expand access to incision-free women’s healthcare

Mount Sinai becomes first in NYC to deliver incision-free, MRI-guided prostate treatment with Profound’s TULSA-PRO

Subscribe